Breaking News, Financial News

Financial Report: InterMune

Esbriet revenues climb 188%

InterMune

1Q Revenues: $30.3 million (+188%)

1Q Loss: $53.6 million (loss of $49.9 million in 1Q13)

Comments: Esbriet revenue in the quarter was $30.3 million, up 188%. R&D expenses were $32.1 million, up 24%, attributed to activities to complete the ASCEND Phase III trial, a higher number of patients in the RECAP extension study of pirfenidone, and activities related to the pirfenidone NDA resubmission.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters